Page 119 - Read Online

McKenna et al Hypoxia in prostate cancer

D, O’Byrne KJ, Koong AC, Giaccia AJ. An evaluation of tumor (Apaziquone): from the clinic to the laboratory and back again. Br J
oxygenation and gene expression in patients with early stage non- Pharmacol 2013;168:11-8.
small cell lung cancers. Clin Cancer Res 2006;12:1507-14. 105. Hendricksen K, Cornel EB, de Reijke TM, Arentsen HC, Chawla
93. Vaupel P, Mayer A, Briest S, Hockel M. Oxygenation gain factor: a S, Witjes JA. Phase 2 study of adjuvant intravesical instillations of
novel parameter characterizing the association between hemoglobin apaziquone for high risk nonmuscle invasive bladder cancer. J Urol
level and the oxygenation status of breast cancers. Cancer Res 2012;187:1195-9.
2003;63:7634-7. 106. Meng FY, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G,
94. Koong AC, Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Duan JX, Cai XH, Mowday AM, Guise CP, Maroz A, Anderson
Bastidas AJ, Vierra M. Pancreatic tumors show high levels of RF, Patterson AV, Stachelek GC, Glazer PM, Matteucci MD, Hart
hypoxia. Int J Radiat Oncol Biol Phys 2000;48:919-22. CP. Molecular and cellular pharmacology of the hypoxia-activated
95. Graffman S, Bjork P, Ederoth P, Ihse I. Polarographic pO2 prodrug TH-302. Mol Cancer Ther 2012;11:740-51.
measurements of intra-abdominal adenocarcinoma in connection 107. Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC,
with intraoperative radiotherapy before and after change of oxygen George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC,
concentration of anaesthetic gases. Acta Oncol 2001;40:105-7. Hurwitz HI. Phase I study of pazopanib plus TH-302 in advanced
96. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Pinover WH, solid tumors. Cancer Chemother Pharmacol 2017;79:611-9.
Greenberg RE, Stobbe C, Hanks GE. Hypoxia in human prostate 108. Badar T, Handisides DR, Benito JM, Richie MA, Borthakur G,
carcinoma: an Eppendorf PO2 study. Am J Clin Oncol 2001;24:458- Jabbour E, Harutyunyan K, Konoplev S, Faderl S, Kroll S, Andreeff
61. M, Pearce T, Kantarjian HM, Cortes JE, Thomas DA, Konopleva
97. Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, M. Phase I study of evofosfamide, an investigational hypoxia-
Catton C, Catton P, Crook J, Gospodarowicz M, McLean M, Warde activated prodrug, in patients with advanced leukemia. Am J Hematol
P, Hill RP. Polarographic electrode study of tumor oxygenation in 2016;91:800-5.
clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 109. Patterson AV, Silva S, Guise C, Bull M, Abbattista M, Hsu A, Sun
2004;58:750-7. JD, Hart CP, Pearce TE, Smaill JB. TH-4000, a hypoxia-activated
98. Movsas B, Chapman JD, Horwitz EM, Pinover WH, Greenberg EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative
RE, Hanlon AL, Iyer R, Hanks GE. Hypoxic regions exist in human NSCLC. J Clin Oncol 2015;33:e13548.
prostate carcinoma. Urology 1999;53:11-8. 110. Guise CP, Mowday AM, Ashoorzadeh A, Yuan R, Lin WH, Wu DH,
99. Lartigau E, Randrianarivelo H, Avril MF, Margulis A, Spatz A, Smaill JB, Patterson AV, Ding K. Bioreductive prodrugs as cancer
Eschwege F, Guichard M. Intratumoral oxygen tension in metastatic therapeutics: targeting tumor hypoxia. Chin J Cancer 2014;33:80-6.
melanoma. Melanoma Res 1997;7:400-6. 111. McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu YC,
100. Kallinowski FBH. Can the oxygenation status of rectal carcinomas Wilson WR, Melink TJ, Tchekmedyian NS. PR-104 a bioreductive
be improved by hypoxia? In: Vaupel P, Kelleher DK, Günderoth M, pre-prodrug combined with gemcitabine or docetaxel in a phase
editors. Tumor oxygenation. Stuttgart, Germany: Gustav Fischer; Ib study of patients with advanced solid tumours. BMC Cancer
1995. p. 291-6. 2012;12:496.
101. Mattern J, Kallinowski F, Herfarth C, Volm M. Association of 112. Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB,
resistance-related protein expression with poor vascularization Rockwell S, Sartorelli AC, Ross DA, Sasaki CT, Fischer JJ.
and low levels of oxygen in human rectal cancer. Int J Cancer Concurrent chemo-radiotherapy with mitomycin C compared with
1996;67:20-3. porfiromycin in squamous cell cancer of the head and neck: final
102. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson results of a randomized clinical trial. Int J Radiat Oncol Biol Phys
LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman 2005;61:119-28.
B, Ayoub J, Richrdson G, Dunlop D, Arcenas A, Vescio R, Viallet J, 113. Panettiere FJ, Talley RW, Torres J, Lane M. Porfiromycin in
Treat J. Tirapazamine plus cisplatin versus cisplatin in advanced non- management of epidermoid and transitional cell-cancer - phase II
small-cell lung cancer: a report of the international CATAPULT I study. Cancer Treat Rep 1976;60:907-11.
study group. J Clin Oncol 2000;18:1351-9. 114. Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, Dickinson G,
103. Marcu L, Olver I. Tirapazamine: from bench to clinical trials. Curr Aarons L, Watson A, Jowle D, Cummings J, Robson L, Halbert G, Dive
Clin Pharmacol 2006;1:71-9. C, Ranson M. Phase I pharmacokinetic and pharmacodynamic study of
104. Phillips RM, Hendriks HR, Peters GJ, Grp E-PMM. EO9 the bioreductive drug RH1. Cancer Treat Rep 2011;22:1653-60.

Journal of Cancer Metastasis and Treatment ¦ Volume 4 ¦ March 1, 2018 13